Potassium deficiency can progress from diffuse muscle weakness to flaccid paralysis, and in severe hypokalemia this paralysis may involve the diaphragm and other respiratory muscles, resulting in hypoventilation and acute respiratory failure. In these situations, patients often present with ascending weakness, areflexia, and shortness of breath or an inability to take a deep breath, and may require urgent ventilatory support while intravenous potassium is carefully replaced. Case reports and cohort data show that even admission potassium values just below the normal range are associated with a higher risk of needing mechanical ventilation in hospitalized patients, underscoring the importance of promptly recognizing and correcting hypokalemia before it reaches paralysis‑level severity. This medication is commonly used for Hypertension.
Haddad S, Arabi Y, Shimemeri AA. Hypokalemic paralysis mimicking Guillain-Barré syndrome and causing acute respiratory failure. Middle East J Anaesthesiol. 2004 Jun;17(5):891-7. PMID: 15449746. Wu CZ, Wu YK, Lin JD, Kuo SW. Thyrotoxic periodic paralysis complicated by acute hypercapnic respiratory failure and ventricular tachycardia. Thyroid. 2008 Dec;18(12):1321-4. Ayyawar H, et al. Hypokalemic Paralysis Leading to Respiratory Failure: An Unusual Presentation of Sjogren’s Syndrome. Austin Crit Care Case Rep. 2021; 5(3): 1030. Sobrosa P Sr, Ferreira Â, Vilar da Mota R, Couto J, Sousa L. Severe Hypokalemia and Respiratory Muscle Paralysis: An Atypical Manifestation of Primary Sjögren's Syndrome. Cureus. 2024 Dec 23;16(12):e76240.
Some side effects may be linked to nutrient depletion caused by this medication.
An increased excretion of potassium can occur in people taking calcium channel blocker drugs like felodipine. Supplementation may need to be considered if blood levels of potassium are low.
Studies suggest that Felodipine, a type of calcium channel blocker (CCB), may increase the excretion of calcium in the urine. While the long-term effects on bone health are unclear, some healthcare professionals suggest calcium supplementation for patients taking felodipine, especially those at higher risk of osteoporosis.
Research suggests that Felodipine, a type of calcium channel blocker (CCB), may increase the excretion of magnesium in the urine. This can potentially lead to magnesium deficiency. Studies have shown an increase in fractional excretion of magnesium following felodipine treatment, and the drug may also alter how magnesium moves across red blood cell membranes. Therefore supplementation with magnesium should be considered when on this therapy.